Man Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Man Group’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.28M	Buy	61,043 +13,463	+28%	+$500K	﹤0.01%	1509
2026 Q1	$1.73M	Sell	47,580 -14,980	-24%	-$669K	﹤0.01%	1631
2025 Q4	$2.91M	Buy	+62,560	New	+$2.79M	0.01%	1305
2024 Q4	–	Sell	-100,188	Closed	-$5.12M	–	2022
2024 Q3	$5.12M	Sell	100,188 -25,526	-20%	-$1.32M	0.01%	1016
2024 Q2	$5.63M	Buy	+125,714	New	+$5.81M	0.01%	961
2023 Q3	–	Hold	0	–	–	–	1360

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Man Group's CRNX Position: Q2 2026 in Review

Man Group increased its Crinetics Pharmaceuticals (CRNX) stake by 28% in Q2 2026, buying an estimated $500K and bringing the position to 61,043 shares worth $2.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1509.

Man Group first reported a position in CRNX in Q2 2024 and has held it in 5 quarters since. The position peaked at $5.63M in Q2 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Man Group held 61,043 shares of Crinetics Pharmaceuticals worth $2.28M as of Q2 2026.
Man Group bought 13,463 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $500K.
Crinetics Pharmaceuticals made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1509 holding.
Man Group first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
Man Group's Crinetics Pharmaceuticals position peaked at $5.63M in Q2 2024.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.